Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma. Anlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES: To determine the anti-tumor activity of anlotinib hydrochloride (Objective Response rate,ORR) in patients with metastatic pheochromocytomas or paragangliomas. SECONDARY OBJECTIVES: I. To assess safety profile of anlotinib. II. To assess progression-free survival time. III. To assess disease control rate. OUTLINE: Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo urine and blood sample collection, imaging examinations at baseline and periodically during study. After completion of study therapy, patients are followed up every 3-6 months. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04860700
Study type Interventional
Source Peking Union Medical College Hospital
Contact Anli Tong
Phone 13911413589
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date April 17, 2021
Completion date October 17, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02592356 - Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer N/A
Active, not recruiting NCT03008369 - Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1